FDA Clarifies Regenerative Medicine Regulations: Strategic Use of RMAT Designation and HCT/P Classification to Accelerate Development

August 2, 2026

Global MedTech Expert USA

Overview

The U.S. FDA has detailed its Regenerative Medicine Advanced Therapy (RMAT) designation, offering a fast-track development framework for cell and gene therapies targeting serious or life-threatening diseases. Crucially, the correct classification of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) under either the stricter 351 BLA pathway or the more lenient 361 pathway is paramount at early development stages to mitigate regulatory risks. RMAT designation facilitates early, structured dialogue with CBER on manufacturing, non-clinical data, and accelerated approval endpoints.

In Depth

Key Findings: FDA Streamlines Regenerative Medicine Product Development with RMAT and HCT/P Clarifications

The U.S. Food and Drug Administration (FDA) is actively providing comprehensive guidance on its Regenerative Medicine Advanced Therapy (RMAT) designation to expedite the development and approval of Regenerative Medicine Products (RMPs). Established under Section 3033 of the 21st Century Cures Act, RMAT offers a rapid development framework, mirroring the Breakthrough Therapy program, for cell therapies, tissue-engineered products, cell- and tissue-based combination products, and gene-modified cell therapies intended to treat serious or life-threatening conditions. This framework includes early and structured dialogue with the Center for Biologics Evaluation and Research (CBER) regarding manufacturing, non-clinical data, and endpoints for accelerated approval.

Technical and Regulatory Details: The Critical Distinction of 351 BLA vs. 361 HCT/P

Benefits of RMAT Designation: RMAT designation enables close collaboration with the FDA, offering benefits such as priority review, rolling review, and the potential use of surrogate or intermediate endpoints for accelerated approval. This can significantly shorten the development timeline, bringing innovative regenerative medicines to patients faster.
HCT/P Classification Crossroads: The regulatory pathway for Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) hinges on whether the product undergoes ‘minimal manipulation’ and is intended for ‘homologous use.’ If these criteria are not met, the product falls under the more stringent Section 351 Biologics License Application (BLA) regulations, requiring an Investigational New Drug (IND) application and BLA approval. Conversely, products meeting these criteria may be regulated solely under Section 361, bypassing IND and BLA requirements but still adhering to quality system and registration mandates.
Strategic Regulatory Planning: For developers, accurately determining whether a product falls under Section 351 or 361 at the initial stages is paramount. Misclassification can lead to regulatory delays, increased costs, and even market withdrawal. CBER offers consultation services on this classification, emphasizing the value of early engagement.

Background and Industry Context: Adapting Regulation to Innovation

The regenerative medicine sector is experiencing rapid growth driven by innovations in cell and gene therapy, and the FDA is adapting its regulatory environment to safely and swiftly bring these innovations to patients. RMAT designation exemplifies this adaptation, introducing flexibility that acknowledges the unique complexities and high potential benefits of this field compared to traditional pharmaceuticals. The HCT/P classification guidance also serves as a critical tool for managing patient risks associated with unapproved products while supporting the development of effective therapies.

Future Outlook: Evolving Regulatory Landscape and Patient Access

The clarification of RMAT designation and HCT/P classification plays a pivotal role in fostering the development of regenerative medicine products and improving patient access. Going forward, monitoring the clinical progress and approval status of RMAT-designated products will further validate the effectiveness of this framework. Additionally, the specific impact of FDA guidance on Chemistry, Manufacturing, and Controls (CMC) development, along with new interpretations or cases in HCT/P regulatory classification, will be essential for understanding broader industry trends. Continued dialogue and cooperation between regulatory bodies and developers will be key to shaping the future of regenerative medicine.

Source: https://meddeviceguide.com/blog/fda-regenerative-medicine-351-361-rmat-designation-guide

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.